SID 0002 Myriad Genetics

Stocks-in-Depth

English - November 02, 2015 16:45 - 55 minutes - 50.8 MB - ★★★★ - 9 ratings
Investing Business News Business News competitiveanalysis investing analysis contrarian equityresearch financialmodel garp growth investment investmentresearch Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: SID 0001 Monotype Imaging

Next Episode: SID 0003 Synaptics

In Myriad's analyst day in NYC on September 14, 2015, management discussed the outlook for several new growth drivers, and it addressed challenges faced in its legacy BRCA1/2 hereditary cancer genetic testing franchise. We explore what's new, the ins and outs of each opportunity, and delve into the intricacies of companion diagnostics.